214 related articles for article (PubMed ID: 17194384)
1. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Sirvent E; Ruiz M; Rodríguez JC; Royo G
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
3. Benzalkonium chloride enhances antibacterial activity of gatifloxacin and reduces its propensity to select for fluoroquinolone-resistant strains.
Hesje CK; Borsos SD; Blondeau JM
J Ocul Pharmacol Ther; 2009 Aug; 25(4):329-34. PubMed ID: 19650708
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
5. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
[TBL] [Abstract][Full Text] [Related]
6. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
7. [Mutant-prevention concentration: a new, clinically relevant parameter of antimicrobial activity?].
Cantón R
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):599-602. PubMed ID: 17194383
[No Abstract] [Full Text] [Related]
8. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Hansen GT; Zhao X; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Blondeau JM; Borsos S; Hesje CK
J Chemother; 2007 Apr; 19(2):146-51. PubMed ID: 17434822
[TBL] [Abstract][Full Text] [Related]
10. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
[TBL] [Abstract][Full Text] [Related]
11. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Hedlin P; Blondeau JM
Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
[TBL] [Abstract][Full Text] [Related]
12. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
[TBL] [Abstract][Full Text] [Related]
13. [The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].
Sun ST; Chen ZJ; Xu J; Tian XL
Zhonghua Yan Ke Za Zhi; 2006 Nov; 42(11):989-91. PubMed ID: 17386136
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Allen GP; Hankins CD
J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of fluoroquinolones against common respiratory pathogens.
Aydemir S; Tunger A; Cilli F
West Indian Med J; 2006 Jan; 55(1):9-12. PubMed ID: 16755812
[TBL] [Abstract][Full Text] [Related]
17. Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers.
Stein GE; Schooley S
Int J Antimicrob Agents; 2004 Aug; 24(2):168-72. PubMed ID: 15288316
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Patel SN; McGeer A; Melano R; Tyrrell GJ; Green K; Pillai DR; Low DE;
Antimicrob Agents Chemother; 2011 Aug; 55(8):3703-8. PubMed ID: 21628545
[TBL] [Abstract][Full Text] [Related]
19. Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different!
Jones RN; Beach ML; Pfaller MA
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):161-3. PubMed ID: 11750171
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
